About Us

A Team of Experts, Researchers & Advisors

AMP Discovery Logo
Menu

Our MIssion

Our mission is to overcome global bacterial resistance by replacing existing antibiotics with proprietary antimicrobial peptides (AMPs), which will be used as therapeutic solutions for the treatment of systemic infectious diseases caused by Gram-negative bacteria, including antibiotic-resistant Gram-negative bacteria.

Research Division

Robert Hodges Headshot

Robert Hodges, Ph.D., FRSC

Founder & CSO

Professor of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, John Stewart Endowed Chair in Peptide Chemistry. In 2017 received the most prestigious award in peptide chemistry, the Bruce Merrifield Award, for outstanding lifetime accomplishment in peptide research recognizing the highest level of scientific creativity. Prior experience, Director and CEO of the Protein Engineering Network of Centers of Excellence; S.P.I. Synthetic Peptides, Inc.; Cytovax Biotechnologies, Inc.; BioAMPs International, Inc. and PeptiVir, Inc.

Awards & Accolades

The Fellowship of the Royal Society of Canada is an award granted to individuals that the Royal Society of Canada judges to have made remarkable contributions in the arts, humanities and sciences, as well as in Canadian public life.

The MRC career awards were considered the most prestigious of such awards in Canada.

Awarded by The Canadian Society of Biochemistry and Molecular Biology in recognition of a record of outstanding achievements in research in the field of biochemistry undertaken in Canada by a Canadian Scientist.

Outstanding leadership in Alberta science from the ASTech Foundation.

Honored by the American Peptide Society for outstanding achievements in peptide research.

Received from the University of Colorado, Denver. 

Received from the University of Colorado Denver.

Won from the American Peptide Society for career-long research excellence in the field of peptide science and significant mentorship and training of students, postdoctoral fellows and other co-workers.

The Royal Society of Canada appointed Dr. Hodges as a "Life Member".

Received from the American Peptide Society for outstanding lifetime accomplishment in peptide research, recognizing the highest level of scientific creativity.

Lajos Gera Headshot

Lajos Gera, Ph.D.

Expert in Organic and Peptide Chemistry.

Research Associate Professor in Biochemistry and Molecular Genetics, University of Colorado School of Medicine. Expert in Peptide Chemistry. Prior experience, Breceptin, B9870 cytolytic bradykinin antagonist peptide dimer drug development, which was approved by the Food and Drug Administration (FDA) on December 4, 2009 (IND 107,125) to proceed to clinical trial by Apoplogic Pharmaceuticals for the treatment of lung cancer.

Colin Mant Headshot

Colin Mant, Ph.D.,

Director of Analytical Chemistry

Worked with Dr. Hodges for over 35 years, both at the University of Alberta and the University of Colorado, School of Medicine. Outstanding achievements in the area of high-performance liquid chromatography and biochemistry.

Scientific Advisory Board

Robert Hodges, Ph.D., FRSC

Robert Hodges, Ph.D., FRSC

Founder & CSO

Professor of Biochemistry and Molecular Genetics, University of Colorado School of Medicine, John Stewart Endowed Chair in Peptide Chemistry. In 2017 received the most prestigious award in peptide chemistry, the Bruce Merrifield Award, for outstanding lifetime accomplishment in peptide research recognizing the highest level of scientific creativity. Prior experience, Director and CEO of the Protein Engineering Network of Centers of Excellence; S.P.I. Synthetic Peptides, Inc.; Cytovax Biotechnologies, Inc.; BioAMPs International, Inc. and PeptiVir, Inc.

Tomi K. Sawyer

Tomi K. Sawyer

Peptide Drug Hunter (SAB), AMP Discovery

Tomi K. Sawyer has recently retired as Distinguished Scientist, Global Chemistry at Merck & Company, Inc., where he created a Peptide Drug Hunter Network of more than 100+ scientists actively engaged in peptide drug discovery, core capabilities and a knowledge engine. Currently, Tomi is advancing the founding of a Peptide Drug Hunter Consortium, a non-profit global network to empower the advancement of peptide preclinical research and clinical development at the interface of academia, biotech/pharma and investors.

Richard Duke, Ph.D.

Richard Duke, Ph.D.

Consultant

Serial entrepreneur (Globe immune, Apologic Pharmaceuticals, MenoGeniX). Associate Professor Medicine (Medical Oncology), University of Colorado, School of Medicine. Founder and CSO, Colorado Institute for Drug, Device and Diagnostic Development. Prior experience Janus Capital, Duke Medical Research Group.

Advisors

Randy Irvin, Ph.D.

Randy Irvin, Ph.D.

Consultant

Professor Emeritus, Department of Medical Microbiology and Immunology, University of Alberta. Expert in microbiology and immunology with a focus on the bacterial pathogen Pseudomonas aeruginosa. Prior experience S.P.I. Synthetic Peptides, Inc., Cytovax Biotechnologies, Inc. and Arch Biopartners, Inc.

David DeLong, Ph.D.

David DeLong, Ph.D.

Consultant

A 30-year pharmaceutical industry veteran with commercial and general management experience with both small and large biopharma companies. Prior experience: Vinden Pharma, LLC; BioAMPS International, Inc.; Allos Therapeutics, Inc.; Genentech, Inc.

David F. Carmichael, Ph.D.

David F. Carmichael, Ph.D.

Consultant

Biopharmaceutical Product Development. His expertise in development of peptide and protein therapeutics has been developed through 35 years of pharmacology work in the biotechnology industry. Prior experience: Aerie BioConsulting, LLC; Xencor, Inc.: FibroGen, Inc.; Synergen, Inc.

Praful Shah, Ph.D.

Praful Shah, Ph.D.

Consultant

Consultant, pharmaceutical scientist with experience in product development from inception to market launch. Worked in large pharmaceutical and small biotech companies. Prior experience: PharmiOhm; Myogen/Gilead Colorado; Sanofi Aventis and Pfizer.

Contact Us
X
AMP Discovery Logo